

National Board of Examinations

Question Paper Name :	DrNB Medical Oncology Paper2
Subject Name :	DrNB Medical Oncology Paper2
Creation Date :	2022-12-22 19:38:11
Duration :	180
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

DrNB Medical Oncology Paper2

Group Number :	1
Group Id :	3271871323
Group Maximum Duration :	0
Group Minimum Duration :	180
Show Attended Group? :	No
Edit Attended Group? :	No
Group Marks :	100
Is this Group for Examiner? :	No
Examiner permission :	Cant View
Show Progress Bar? :	No

DrNB Medical Oncology Paper2

Section Id :	3271871326
Section Number :	1
Section type :	Offline

Mandatory or Optional :	Mandatory
Number of Questions to be attempted :	10
Section Marks :	100
Enable Mark as Answered Mark for Review and Clear Response :	Yes
Maximum Instruction Time :	0
Sub-Section Number :	1
Sub-Section Id :	3271871330
Question Shuffling Allowed :	No
Is Section Default? :	null

Question Number : 1 Question Id : 32718712282 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

- Discuss the pathological and molecular types of endometrial cancer. [5]
- Discuss the role of pelvic and para aortic lymphadenectomy in treatment of early stage endometrial cancer. [5]

Question Number : 2 Question Id : 32718712283 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- Discuss the epidemiology and aetiology of epithelial ovarian cancer. [5]
- Describe the various types of sex cord stromal cell tumours of the ovary with a brief mention of

their clinical features. [5]

Question Number : 3 Question Id : 32718712284 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

a) Discuss the epidemiology and aetiological factors in HNSCC in India. [6]

b) Discuss with neat diagram various types of cervical lymphadenectomy. [4]

Question Number : 4 Question Id : 32718712285 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

a) Discuss with a diagram the steps involved in next-generation sequencing technology. [4]

b) Briefly discuss the various techniques used for estimation of minimal residual disease (MRD) in hematological cancers. [4]

c) Discuss the limitations of next-generation sequencing. [2]

Question Number : 5 Question Id : 32718712286 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

a) Describe the histological classification (grading) of pancreatic neuroendocrine tumour based on mitotic count or KI 67 index. [5]

b) Discuss the role of PRRT in metastatic neuroendocrine tumours of pancreas. [5]

Question Number : 6 Question Id : 32718712287 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

a) Discuss the updated disease specific graded prognostic assessment (GPA) system for management of brain metastasis. [5]

b) Define leptomeningeal metastasis and discuss its management. [5]

Question Number : 7 Question Id : 32718712288 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

a) Discuss the pathophysiology of malignant ascites and list 3 most cancers causing ascites in males and females. [6]

b) Describe the various options available for management of malignant ascites. [4]

Question Number : 8 Question Id : 32718712289 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

a) Discuss the principles of antifungal therapy in febrile neutropenia. [5]

b) Define catheter related bloodstream infection (CRBSI) and discuss its management in relation to PICC line/ Chemoport. [5]

Question Number : 9 Question Id : 32718712290 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

a) Discuss dermatological toxicities related to anti-neoplastic agents. [5]

b) Discuss the management of chemotherapy induced anaemia. [5]

Question Number : 10 Question Id : 32718712291 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) Discuss the pathogenesis of retinoblastoma with neat diagram. [5]
- b) Name the chemotherapeutic agents that are active in retinoblastoma. Discuss briefly intra-arterial chemotherapy for retinoblastoma. [5]